A take on business from Times Square
Sponsored by NYC News Service and CUNY Newmark J-School
Section
Antidepressant drugs have been on the market since the 1950s, but Axsome Therapeutics is betting its new treatment will have a major impact on patients and doctors.
Axsome Therapeutics Inc. has two central nervous system products on the market that have the industry buzzing around the small biotech company.
Axsome Therapeutics Inc. plans to resubmit its New Drug Application for its product which is designed to aid in the treatment of acute migraines to the U.S.
About the Journal
The Times Square Investment Journal covers companies, markets and personal finance from a newsroom in the heart of Manhattan. The Journal is sponsored by the NYC News Service and the Craig Newmark Graduate School of Journalism at CUNY.
Send comments and story tips to the editor.
greg.david@journalism.cuny.edu